Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study / Fenaux, P; Mufti, Gj; Hellstrom Lindberg, E; Santini, Valeria; Finelli, C; Giagounidis, A; Schoch, R; Gattermann, N; Sanz, G; List, A; Gore, Sd; Seymour, Jf; Bennett, Jm; Byrd, J; Backstrom, J; Zimmerman, L; Mckenzie, D; Beach, C; Silverman, Lr; Sacchi, S; Bosi, Alberto; Musto, P; Muus, P.. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - ELETTRONICO. - 10:(2009), pp. 223-232.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
SANTINI, VALERIA;BOSI, ALBERTO;
2009
Abstract
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.File | Dimensione | Formato | |
---|---|---|---|
lancet.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
231.52 kB
Formato
Adobe PDF
|
231.52 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.